Prior Bare Metal Stent Restenosis as a Predictor for Subsequent Restenosis: The Lightning Often Strikes Twice

Patients with Good Collateralization May Profit from Cilostazol

“…Another oral drug showing promising results is rapamycin [3]. The most established strategy to reduce the restenosis risk, however, is the use of drug-eluting stents instead of bare metal stents [4,5]. As we know, drug-eluting stents have their draw backs such as higher costs and the need for longer-term dual antiplatelet therapy.…”